EBT Medical, Inc., a 2018 UTEST company, is developing disruptive neuromodulation therapies for pelvic health disorders, recently secured a USD$10M Series A investment, co-led by two top-tier venture capital firms, SV Health Investors and Genesys Capital.

EBT intends to use the funding to further develop its revolutionary noninvasive neuromodulation technology, as well as to pursue additional clinical data validating its safety and effectiveness. Funding will also be used to expand the management team and for general administrative purposes.

Full story @ –
https://ebtmedical.com/wp-content/uploads/2019/11/2019-11-18_EBT-Medical_EBT_Series_A_vF_v11.pdf